Trial Profile
A Three-Month Open-Label Treatment Extension of Protocol MNTX 302
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 May 2019
Price :
$35
*
At a glance
- Drugs Methylnaltrexone bromide (Primary)
- Indications Constipation
- Focus Adverse reactions
- Sponsors Progenics Pharmaceuticals
- 01 Aug 2018 New trial record